Vincent Vultaggio
Known title: Principal Accounting OfficerCIK: 0002018766
Associated companies
Transaction History
| ZNTL | ▼ Sell | Open Market | 6,894 | $17K | 2/10/2026 | View on chart |
| ZNTL | ▼ Sell | Open Market | 3,379 | $8K | 2/9/2026 | View on chart |
| ZNTL | ▼ Sell | Open Market | 29,951 | $73K | 2/6/2026 | View on chart |
| ZNTL | ▼ Sell | Open Market | 556 | $1K | 2/3/2026 | View on chart |
| ZNTL | ▼ Sell | Open Market | 2,540 | $6K | 2/2/2026 | View on chart |
| ZNTL | ▲ Buy | Grant | 158,586 | $0 | 2/3/2025 | View on chart |
| ZNTL | ▼ Sell | Open Market | 2,615 | $4K | 2/3/2025 | View on chart |
| ZNTL | ▼ Sell | Open Market | 1,603 | $5K | 10/4/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Leerink Partners initiates coverage of Zentalis at Outperform
Leerink Partners has begun covering Zentalis Pharmaceuticals with an Outperform rating and a price target of $8. This new analyst note places the target above the current average analyst estimate of $6.89. The move adds to the recent analyst activity surrounding the stock, which is currently trading near its 52-week range midpoint.
Leerink Partners initiates coverage of Zentalis at Outperform. Leerink Partners has begun covering Zentalis Pharmaceuticals with an Outperform rating and a price target of $8. This new analyst note places the target above the current average analyst estimate of $6.89. The move adds to the recent analyst activity surrounding the stock, which is currently trading near its 52-week range midpoint.